

Inmedix® introduces the new CloudHRV™ clinical diagnostic to the 2025 Life Science Innovation Northwest Conference

Precision, 5-minute, heart rate variability (HRV) managed in the cloud recently cleared by the FDA.

NORMANDY PARK, WA, UNITED STATES, April 17, 2025 /EINPresswire.com/ -- Seattle-based medtech/biotech [Inmedix](#), Inc. was selected to present at the Life Science Innovation Northwest conference 2025 (LSINW) held at the

Seattle Convention Center in Seattle, WA on Wednesday, April 23, 2025. Inmedix CEO Andrew J Holman MD will share how heart rate variability (HRV) has advanced into a precision, clinical diagnostic recently cleared by the FDA for US commercialization. Celebrating its 25th year, LSINW is the largest annual life science event in the Pacific Northwest and is sponsored by Life Science Washington, an independent trade association serving the life sciences industry in the state of Washington.

HRV applies sophisticated mathematical analyses to quantify the impact of autonomic nervous system (ANS) stress on cardiac rhythm. Consumer applications are numerous and appropriate for wellness and training, but none have sufficiently accurate hardware or software for medical care and regulatory clearance.

Inmedix CloudHRV is the first system cleared by the FDA as a cloud-based, HRV diagnostic calculated from a high-fidelity 5-min electrocardiogram (ECG) which also includes Baevsky indices of parasympathetic and sympathetic ANS brain activity. It represents a milestone in modern HRV assessment with scalability, precision and affordability for patients and their caregivers in the clinical setting.

HRV provides indirect measures of the sympathetic (fight-or-flight) and parasympathetic (rest/restorative) components of the human ANS within the brain. For medical grade HRV, a precision ECG is required to identify each heartbeat and to measure the precise timing between beats. These ECG measurements of heart rate (pulse) variability over time reflect how the ANS influences cardiac rhythm during respiration. Subsequently, mathematical formulae can be



applied to render HRV indices of central brain sympathetic and parasympathetic activity.

“Availability of an accurate, non-invasive, 5-min, diagnostic like CloudHRV is a long-awaited milestone for patients and clinical medicine,” said Andrew J Holman MD, Seattle rheumatologist and CEO & Co-founder of Inmedix, Inc. “Quantifying the autonomic nervous system (ANS) stress state with FDA-cleared precision may offer an historic opportunity to more comprehensively understand disease processes and to formulate more effective care across a broad spectrum of medical disciplines.”

About Inmedix, Inc. and its subsidiary, Inmedix UK, Ltd.

Seattle-based biotech/medtech Inmedix, Inc. and its subsidiary Inmedix UK, Ltd., are committed to engaging in world class research to discover innovative solutions for pressing healthcare needs related to the impact of stress modulated within the brain by the autonomic nervous system (ANS).

NOTICE:

This Press Release contains certain forward-looking statements, including without limitation statements regarding Inmedix’s plans for preclinical studies, effectiveness of its research, product capabilities and the market’s demand for its respective products. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Inmedix’s business which could significantly affect expected results, including without limitation, progress of development, clinical testing, regulatory approval, developments in raw material, personnel costs, sales as well as legislative, fiscal, and other regulatory measures. Any forward-looking statements are qualified in their entirety by this cautionary statement, and Inmedix undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. This is not an offer to sell or an offer to purchase securities.

Andrew Holman

Inmedix Inc.

+1 206-412-5347

andrew.holman@inmedix.com

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/804128694>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.